6 research outputs found

    Chamber-specific alterations of noradrenaline uptake (uptake(1)) in right ventricles of monocrotaline-treated rats

    No full text
    1. In rats a single injection of the alkaloid monocrotaline (60 mg MCT kg(−1) body weight, i.p.) caused right ventricular hypertrophy and heart failure. The aim of this study was to find out whether, in these MCT-treated rats, the cardiac neuronal noradrenaline uptake (uptake(1)) might undergo chamber-specific alterations. 2. For this purpose we assessed in right and left ventricular slices, uptake(1) activity (by [(3)H]-noradrenaline accumulation), and in right and left ventricular membranes, uptake(1) carrier protein density (by [(3)H]-nisoxetine binding). 3. Uptake(1)-inhibitors blocked [(3)H]-noradrenaline accumulation in ventricular slices and [(3)H]-nisoxetine binding in ventricular membranes with the order of potency: desipramine>nisoxetine>>cocaineâ©ŸGBR 12909, indicating that with both approaches noradrenaline uptake(1) was determined. 4. In right ventricular slices of MCT-treated rats uptake(1) activity was significantly lower than in control rats (84.7±8.2 vs 145.1±6.2 pmol noradrenaline mg(−1) tissue 15 min(−1); P<0.05). This was accompanied by a significant decrease in the density of [(3)H]-nisoxetine binding sites (73.7±14.4 vs 125.9±9.1 fmol mg(−1) protein; P<0.05). 5. In left ventricular slices of MCT-treated rats uptake(1) activity was not significantly altered (131.2±10.5 vs 116.1±5.2 pmol noradrenaline mg(−1) tissue 15 min(−1)); similarly, also the density of [(3)H]-nisoxetine binding sites was unchanged (108±9.7 vs 123±7.7 fmol mg(−1) protein). 6. We conclude that in MCT-treated rats with right ventricular hypertrophy and heart failure uptake(1) activity is chamber-specifically reduced possibly due to a decrease in carrier protein density
    corecore